Revance Therapeutics, Inc. Business Operations Contracts & Agreements
17 Contracts & Agreements
- Collaboration Agreements (2 contracts)
- Development Agreements (3)
- Distribution Agreements (4)
- Sales Agreements (1)
- Services Agreements (3)
- Supply Agreements (1)
- Termination Agreements (2)
- Voting Agreements (1)
- Third Amendment to Exclusive Distribution Agreement dated December 22, 2022, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on February 28, 2023)
- Second Amendment to Exclusive Distribution Agreement, dated November 18, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on November 8, 2022)
- Technology Transfer, Validation and Commercial Fill/Finish Services Agreement dated March 14, 2017 between Revance Therapeutics, Inc. and Ajinomoto Althea, Inc (Filed With SEC on February 28, 2022)
- Commercial Supply Agreement, effective as of April 6, 2021, by and between Revance Therapeutics, Inc. and Lyophilization Services of New England, Inc (Filed With SEC on August 5, 2021)
- Amendment No. 1 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement dated December 18, 2020 between Revance Therapeutics, Inc. and Ajinomoto... (Filed With SEC on February 25, 2021)
- First Amendment to Exclusive Distribution Agreement (Filed With SEC on November 9, 2020)
- Form of Voting Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein (Filed With SEC on June 10, 2020)
- Exclusive Distribution Agreement, dated January 10, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA (Filed With SEC on February 26, 2020)
- Amendment #1 to the Collaboration and License Agreement dated August 22, 2019 between Revance Therapeutics, Inc. and Mylan Ireland Ltd (Filed With SEC on November 4, 2019)
- First Amendment to Manufacture and Development Agreement dated April 13, 2018 between the Company and Bachem Americas, Inc (Filed With SEC on August 3, 2018)
- Collaboration and License Agreement by and between the Company and Mylan Ireland Ltd, dated as of February 28, 2018 (Filed With SEC on May 9, 2018)
- Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (Filed With SEC on May 9, 2017)
- REVANCE THERAPEUTICS, INC. $75,000,000 COMMONSTOCK SALES AGREEMENT (Filed With SEC on March 7, 2016)
- SECOND AMENDMENT to DEVELOPMENT AND SUPPLY AGREEMENT between REVANCE THERAPEUTICS, INC. and HOSPIRA WORLDWIDE, INC. (Filed With SEC on November 10, 2015)
- FIRST AMENDMENT TO DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT ___________________________________ (Filed With SEC on May 14, 2015)
- REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN ADOPTED BY BOARD ON: AUGUST 29, 2014 AS AMENDED ON: SEPTEMBER 17, 2014 TERMINATION DATE: AUGUST 29, 2024 (Filed With SEC on November 13, 2014)
- REVANCE THERAPEUTICS, INC. 2014 INDUCEMENT PLAN ADOPTED BY BOARD ON: AUGUST 26, 2014 TERMINATION DATE: AUGUST 26, 2024 (Filed With SEC on August 29, 2014)